With our head office in Stockholm, Sweden, our organisation now spans more than 30 countries, delivering treatments to patients in over 70 countries across the globe.
Reporting of adverse reactions
Patient safety is a priority for Sobi. We collect, analyse and react to any new information about the benefits and risks of our products. If you have information about a side effect or adverse reaction associated with any of our products, these should be reported. Please report any suspected adverse reactions directly to the Medicines and Healthcare Regulatory Authority via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store for the UK or Health Products Regulatory Authority (HPRA), for Ireland at www.hpra.ie.
Adverse events should also be reported to Swedish Orphan Biovitrum Ltd at [email protected] or by calling +44 (0) 800 111 4754.
Product complaints
Please contact [email protected] if you think there may be a defect or quality issue with the Sobi product and provide us with the details.
UK & Ireland office
Swedish Orphan Biovitrum Ltd
Suite 2, Riverside 3
Granta Park, Great Abington
Cambridgeshire, CB21 6AD
+44 (0)1223 891 854
[email protected]
Head office
Swedish Orphan Biovitrum AB
Norra Stationsgatan 93A
Solna
SE-112 76 Stockholm
+46(0)8 697 20 00
[email protected]